secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0000950170-24-050568
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q1 revenue $96.9M (+133% YoY), net income $12.2M; raises FY2024 revenue guide to $390-400M
--------------------------------------------------------------------------------

- Q1 net revenue $96.9M (+133% YoY); net income $12.2M ($0.35 diluted EPS) vs net loss $2.6M in Q1 2023.
- Gross margin 62% (down from 69% YoY) due to higher service revenue mix; operating expenses $47.5M.
- Cash balance $350.2M at March 31, 2024.
- FY2024 revenue guidance raised to $390-400M (from $360-370M), representing 61-66% YoY growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000095017024050568/0000950170-24-050568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000095017024050568/tmdx-20240430.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-050568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer